Literature DB >> 8599236

An altered form of apolipoprotein H binds hepatitis B virus surface antigen most efficiently.

H Mehdi1, X Yang, M E Peeples.   

Abstract

Using recombinant (r)HBsAg as a ligand, we previously found a 46-kDa human plasma protein capable of specific binding, and identified this protein as apolipoprotein H (apo H). Apo H is able to bind to rHBsAg containing only the small S protein, in both ligand blot and enzyme immunoassay systems (H. Mehdi, M.J. Kaplan, F.Y. Anlar, X. Yang, R. Bayer, K. Sutherland, and M.E. Peeples, J. Virol. 68, 2415-2424, 1994). Apo H is a plasma glycoprotein, some of which is associated with lipoproteins, particularly chylomicrons and high-density lipoproteins (HDL). During normal lipid trafficking in the bloodstream, chylomicrons and HDL are targeted to the hepatocyte, the primary host cell for HBV, for degradation. In this report the method of apo H presentation was examined. rHBsAg bound to apo H very poorly if the apo H was coated directly on a microtiter well, or if it was presented in a soluble form. Binding was 100-fold more efficient when apo H was presented as a complex with monoclonal antibody (MAb) P2D4. These results suggest that binding to this MAb alters apo H, making it highly reactive with rHBsAg. Apo H binding to rHBsAg is not dependent on divalent cations and is optimal at pH 6.5-8.0. Removal of lipids from rHBsAg resulted in denaturation, preventing analysis of binding activity. Removal of sialic acid or complete removal of N-linked carbohydrates from apo H did not change its ability to bind rHBsAg, indicating that apo H carbohydrates are not involved in rHBsAg binding. Likewise, chemical modification of the arginine residues of apo H had no effect on binding. However, chemical modification of as few as three of the 29 lysine residues of apo H destroyed binding, indicating that one or a few lysines in apo H are involved in rHBsAg binding.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8599236     DOI: 10.1006/viro.1996.0093

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  A novel stop codon mutation in HBsAg gene identified in a hepatitis B virus strain associated with cryptogenic cirrhosis.

Authors:  Xu Yang; Xiao-Peng Tang; Jian-Hua Lei; Hong-Yu Luo; Yong-Hong Zhang
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

Review 2.  Viral and cellular determinants involved in hepadnaviral entry.

Authors:  Dieter Glebe; Stephan Urban
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

3.  Beta2-GPI: a novel factor in the development of hepatocellular carcinoma.

Authors:  Xue Jing; Yun-Feng Piao; Ye Liu; Pu-Jun Gao
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-04       Impact factor: 4.553

4.  Studies on specific interaction of beta-2-glycoprotein I with HBsAg.

Authors:  Pu-Jun Gao; Yun-Feng Piao; Xiao-Dong Liu; Li-Ke Qu; Yang Shi; Xiao-Cong Wang; Han-Yi Yang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

5.  Recombinant hepatitis B surface antigen and anionic phospholipids share a binding region in the fifth domain of beta2-glycoprotein I (apolipoprotein H).

Authors:  Haider Mehdi; Asma Naqvi; M Ilyas Kamboh
Journal:  Biochim Biophys Acta       Date:  2008-01-12

6.  The receptor for beta(2)GP I on membrane of hepatocellular carcinoma cell line SMMC-7721 is annexin II.

Authors:  Pu-Jun Gao; Yang Shi; Yan-Hang Gao; Ya-Wen Liu; Yan Tan
Journal:  World J Gastroenterol       Date:  2007-06-28       Impact factor: 5.742

Review 7.  The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs.

Authors:  Nidhi Gupta; Milky Goyal; Catherine H Wu; George Y Wu
Journal:  J Clin Transl Hepatol       Date:  2014-09-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.